Recent Updates
Recently added Catalysts

Cidofovir

Phase 2

Cytomegalovirus Retinitis | Small molecule | Infectious Disease |Gilead Sciences, Inc.|Last Updated: Jun 24, 2005

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment48
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00002437The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDSPHASE2 COMPLETED 48 - -Jun 24, 20059 United States, United Kingdom
Unlock Drug Trial Details
Study Design & Arms
PurposeTREATMENT
Interventions
NameTypeDescription
CidofovirDRUG -
ProbenecidDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range13 Years — 60 Years
SexALL
Healthy VolunteersNo
Study Sites9

Inclusion Criteria Concurrent Medication: Allowed: * Antiretroviral agents. * Oral trimethoprim/sulfamethoxazole. * Aerosolized pentamidine. * Dapsone. * Fluconazole. * Rifabutin. * Filgrastim (G-CSF). * p24 vaccine. Patients must have: * Diagnosis of AIDS by CDC criteria. * Diagnosis of periph...

Countries:United StatesUnited Kingdom
Unlock Eligibility Criteria